MV BioTherapeutics SA

We develop live biotherapeutics with multiple human and animal health indications due to adaptive modulation of the gut ecosystem. We are a Swiss microbiome biotherapeutics company, a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona. The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications: ApyraVax with the lead indication of Clostridioides difficile infection. ApyraMed with lead indications as immune modulator in cancer and beneficial for the gut ecosystem. Research experiments and preclinical trials are performed in the research lab hosted at IRB.  The company is looking for seed funding in order to move forward as a fully operational company into clinics with the main indications.